Ascendis Pharma A (ASND) Interest Expense - Deposits (2019 - 2025)
Ascendis Pharma A (ASND) posted Interest Expense - Deposits of -$27.0 million for Q2 2025, down 104.96% sequentially from $544.8 million in Q1 2025, and up 59.22% YoY from -$17.0 million in Q2 2024.
Ascendis Pharma A (ASND) Interest Expense - Deposits (2019 - 2025) Analysis & Trends
Ascendis Pharma A has reported Interest Expense - Deposits for 7 years, with the latest figure at -$27.0 million in Q2 2025.
- Quarterly Interest Expense - Deposits rose 59.22% year-over-year to -$27.0 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $850.1 million (up 203.61% YoY) and the FY2024 annual result came in at $597.9 million, up 40.95% from the prior year.
- Interest Expense - Deposits eased to -$27.0 million in Q2 2025 per ASND's latest filing, from $544.8 million in the prior quarter.
- Over five years, Interest Expense - Deposits peaked at $846.8 million in Q1 2022 and troughed at -$287.4 million in Q4 2021.
- A 5-year average of $144.6 million and a median of -$39.9 million in 2023 frame the typical range for Interest Expense - Deposits.
- The sharpest annual moves came in 2021 and 2024: Interest Expense - Deposits slumped 262.51% in 2021, then soared 686.6% in 2024.
- Over 5 years, Interest Expense - Deposits stood at -$287.4 million in 2021, then jumped by 37.44% to -$179.8 million in 2022, then soared by 70.61% to -$52.8 million in 2023, then plunged by 33.43% to -$70.5 million in 2024, then soared by 61.66% to -$27.0 million in 2025.
- According to Business Quant data, Interest Expense - Deposits over the past three periods registered -$27.0 million, $544.8 million, and -$70.5 million for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense - Deposits (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -27.03 Mn |
| Mar 31, 2025 | 544.80 Mn |
| Dec 31, 2024 | -70.50 Mn |
| Sep 30, 2024 | 402.85 Mn |
| Jun 30, 2024 | -66.27 Mn |
| Mar 31, 2024 | 347.90 Mn |
| Dec 31, 2023 | -52.83 Mn |
| Sep 30, 2023 | 51.21 Mn |
| Jun 30, 2023 | -116.58 Mn |
| Mar 31, 2023 | 538.05 Mn |
| Dec 31, 2022 | -179.78 Mn |
| Sep 30, 2022 | -66.77 Mn |
| Jun 30, 2022 | -89.90 Mn |
| Mar 31, 2022 | 846.80 Mn |
| Dec 31, 2021 | -287.37 Mn |
| Sep 30, 2021 | 365.42 Mn |
| Jun 30, 2021 | -134.85 Mn |
| Mar 31, 2021 | 597.14 Mn |
| Dec 31, 2020 | -164.33 Mn |
| Sep 30, 2020 | 626.73 Mn |